Skip to content


Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

GSK In China: A Game Changer in Compliance

The entry of the Chinese government into the international fight against corruption and bribery is truly a game-changer. While there may be many reasons for this very public move by the Chinese government, it is clear that foreign companies are now on notice. Doing business the old fashioned way will no longer be tolerated.

The GSK bribery and corruption investigation will be the Number 1 development for the year in anti-corruption compliance. This means that international (read: Western) companies operating in China have a fresh and important risk to consider; that being that they could well be subject to prosecution under domestic Chinese law.

The international component of this investigation may well increase anti-corruption enforcement across the globe. First of all, when other countries notorious for their endemic corruptions, for example India, see that they can attack their domestic corruption by blaming it on international businesses operating in their company; what lesson do you think they will draw? Most probably that all politics are local and when the localities can blame the outsiders for their own problems they will do so. But when that blame is coupled with violations of local law, whether that is anti-bribery or anti-price fixing, there is a potent opportunity for prosecutions.

Just as importantly is the individual perspective. For many Western ex-pats who are considering working in China, this may cause them to rethink whether or not they are willing be stationed in the country for fear of being caught up in the Chinese judicial system, which is a system not known for protecting individual due process rights and this factor cannot be overstated because wherever you do not want to be, imprisoned in China is near the top of the list. 

Just as the Wal-Mart FCPA investigation has reverberated throughout the U.S., I think that the GSK matter will be with us for some time. As bad as it seems about now, and it certainly appears bad, there are many lessons which the compliance practitioner can not only draw from but use for teaching moments within your company. The prior premonition “if you are subjected to a FCPA sweep” may now have changed to “when” so one of those lessons should be expanded to include investigations by local or national officials regarding violations of their own domestic laws against bribery and corruption.

The full eBook GSK in China: Game Changer in Compliance, from which this post is adapted, is available for Kindle on You can order it here.


Thomas Fox is a Contribing Editor of the FCPA Blog. He’s the founder of the Houston-based boutique law firm A popular speaker on compliance and risk-management topics, Fox is also the creator and writer of the widely followed FCPA Compliance and Ethics Blog. His 2012 book Lessons Learned on Compliance and Ethics topped Amazon’s bestseller list for international law. He can be contacted here.

Share this post


1 Comment

  1. Why is this publication not available in Asia & Pacific? I clicked "order it here" from your posting, but Amazon reports "This title is not available for customers from your location in: Asia & Pacific." Given the topic, it seems you are missing out on a large part of your potential customers.

Comments are closed for this article!